Caroline Seymour

Abdulraheem Yacoub, MD, discusses the development of interferon and its current role in the management of patients with MPNs.

According to preliminary findings from the phase Ib KEYNOTE-173 trial, combining the PD-1 inhibitor pembrolizumab with platinum/taxane chemotherapy led to high rates of pathologic complete response in patients with locally advanced triple-negative breast cancer.

According to Huma Q. Rana, MD, genetic testing provides valuable benefit in the treatment landscape of gynecologic cancers. It can inform physicians of the individual and familial risk for developing a malignancy, alert patients of potential screening and preventative measures, and guide selection of potential targeted therapies.

Neelima Denduluri, MD, discusses each CDK4/6 inhibitor as potential first-line and second-line therapies based on the data from the PALOMA-2, MONALEESA-2 and -7, and MONARCH 3 trials, which led to their approvals.

According to the final analysis of the Prostate Cancer Prevention Trial, finasteride, an agent commonly used to treat lower urinary tract problems and baldness in men, was safe and effective in reducing the risk of prostate cancer.

Petros Grivas, MD, PhD, discusses the rapidly evolving locally advanced and metastatic bladder cancer field.

Jonathan L. Wright, MD, MS, FACS, highlighted the available therapies for patients with localized muscle-invasive bladder cancer.

Pashtoon M. Kasi, MD, MBBS, MS,&nbsp;provides an overview of the potential for liquid biopsies in CRC and advances being made in the treatment landscape. &nbsp;<br /> &nbsp;

In findings from the&nbsp;phase II next MONARCH 1 trial, single-agent abemaciclib continued to be safe and effective for patients with hormone receptor&ndash;positive, HER2-negative advanced breast cancer who have progressed on or following endocrine therapy.

In an interview with <em>Targeted Oncology</em>, Robert M. Rifkin, MD, highlighted the results of a trial evaluating the safety of split-dosing administration of daratumumab in patients with multiple myeloma.

Findings of a recent study suggest HPV testing should be incorporated into cervical cancer screening programs. The&nbsp;nested case-control Swedish study&nbsp;found that the presence of&nbsp;specific subtypes of HPV, namely HPV-16 and -18, were associated&nbsp;with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.

Robert Andtbacka, MD,&nbsp;discusses the current use of T-VEC in melanoma and future directions with this type of treatment.

Stephen Oh, MD, PhD,&nbsp;discusses the use of ruxolitinib in patients with myelofibrosis and PV, and emerging agents and next steps in the field of MPNs.

In an interview with <em>Targeted Oncology</em>, Charalambos Andreadis, MD, MSCE, discussed the use of CAR T-cell therapy in patients with DLBCL, as well as the toxicities associated with each product. He also highlights other promising therapies in the treatment landscape.

According to findings of a systematic literature review presented at the 2018 ESMO Congress, the neoadjuvant and metastatic breast cancer settings are appropriate areas to evaluate&nbsp;the equivalence of biosimilars and originator products.

Gilberto Lopes, MD,&nbsp;discusses findings from the phase III KEYNOTE-042 trial and ongoing developments with immunotherapy in NSCLC.

Igor Puzanov, MD, MSCI, FACP, discusses the current and potential future utility of T-VEC in patients with advanced-stage melanoma.

Lloyd Damon, MD,&nbsp;discussed novel therapies in AML with a focus on FLT3 and IDH1/2 inhibitors.<br /> &nbsp;

Rami S. Komrokji, MD,&nbsp;reflects on the diverse treatment landscape of AML and touches on the prognostic importance of biomarkers.

Mazyar Shadman, MD,&nbsp;discusses the evolution of therapy in CLL and how physicians are working to balance these novel agents with additional modalities.<br /> &nbsp;

Peter O&rsquo;Donnell, MD,&nbsp;discusses the integration of immunotherapy in the treatment paradigm of advanced bladder cancer and its potential role as combination therapy.

In an interview with <em>Targeted Oncology</em>, Jay Yang, MD, discussed the evolution of the treatment landscape for AML and the future outlook for these treatments.

Bradley McGregor, MD,&nbsp;discusses the impact of combination therapies on the treatment landscape of renal cell carcinoma.

Joseph Stilwill, MD,&nbsp;addresses recent advancements in melanoma and the focus of research moving forward.

The use of triplet regimens for the treatment of patients with relapsed multiple myeloma has become one of the most favorable treatments recently. OPTIMISMM, a phase III trial, investigated bortezomib and dexamethasone with or without pomalidomide as another triplet regimen option for use in earlier lines of therapy, said Peter Voorhees, MD.<br /> &nbsp;

Treatment of renal cell carcinoma (RCC) is awaiting the potential integration of combinations of immuno-oncology agents like nivolumab (Opdivo) and ipilimumab (Yervoy), or combinations of targeted therapies with checkpoint inhibitors into the treatment paradigm. In an interview with&nbsp;<em>Targeted Oncology</em>, Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

A novel regimen of immunotherapy, angiogenesis inhibition, and chemotherapy brings promising outcomes for patients with non-small cell lung cancer (NSCLC). The synergic combination, notes Benjamin P. Levy, MD, would be exciting to have in the landscape.

Michael A. Morse, MD, discusses a number of key trials that have broadened the treatment landscape of mCRC, the importance of toxicity management in this setting, and other ongoing developments in GI cancers.